| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.76B | 69.94B | 67.71B | 67.97B | 63.37B | 67.89B |
| Gross Profit | 17.06B | 19.00B | 17.29B | 18.94B | 16.84B | 15.47B |
| EBITDA | 5.98B | 7.37B | 3.92B | 7.97B | 10.13B | 8.46B |
| Net Income | 3.84B | 4.43B | 1.58B | 5.28B | 6.86B | 5.41B |
Balance Sheet | ||||||
| Total Assets | 719.73B | 677.46B | 687.58B | 663.07B | 759.71B | 795.15B |
| Cash, Cash Equivalents and Short-Term Investments | 114.77B | 100.57B | 302.05B | 301.91B | 367.50B | 378.51B |
| Total Debt | 19.83B | 18.71B | 18.83B | 17.98B | 17.43B | 18.15B |
| Total Liabilities | 690.53B | 649.75B | 657.33B | 632.95B | 691.96B | 720.33B |
| Stockholders Equity | 28.94B | 27.45B | 30.02B | 29.88B | 67.48B | 74.56B |
Cash Flow | ||||||
| Free Cash Flow | 15.14B | 15.12B | 14.26B | 11.37B | 12.83B | 11.51B |
| Operating Cash Flow | 15.14B | 15.12B | 14.26B | 11.37B | 12.83B | 11.51B |
| Investing Cash Flow | -16.68B | -11.49B | -10.25B | -2.62B | -11.19B | -18.57B |
| Financing Cash Flow | 642.00M | -3.13B | -2.94B | -9.95B | -1.38B | 10.73B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $57.04B | 14.19 | 15.58% | 2.06% | 2.31% | 15.46% | |
76 Outperform | $37.88B | 14.83 | 8.36% | 4.99% | -19.35% | -35.23% | |
72 Outperform | $12.58B | 14.65 | 8.35% | 2.37% | 1.80% | -44.44% | |
71 Outperform | $10.44B | 9.50 | 22.28% | 0.79% | 3.73% | 17.47% | |
70 Outperform | $7.78B | 3.68 | 21.66% | 4.39% | 35.76% | 636.97% | |
69 Neutral | $50.25B | 14.36 | 12.84% | 2.95% | 0.82% | 7.18% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
MetLife, Inc. is a leading global financial services company, providing insurance, annuities, employee benefits, and asset management services, with operations in over 40 markets worldwide. In its third quarter of 2025 earnings report, MetLife showcased robust financial performance, driven by strong variable investment income and strategic growth initiatives. The company reported a 21% increase in adjusted earnings per share, excluding notable items, highlighting the effectiveness of its diversified business model and disciplined execution of its New Frontier strategy.
MetLife’s recent earnings call conveyed a generally positive sentiment, highlighting significant growth in earnings and strong performances in key segments like PRT and Asia. Despite facing challenges such as the impact of the Mexican tax law change and reduced earnings from reinsurance transactions, the positive aspects of the results were predominant.
MetLife, Inc. announced its third-quarter 2025 financial results, reporting a net income of $818 million, or $1.22 per share, and adjusted earnings of $1.6 billion, marking a 15% increase from the previous year. The company experienced growth in variable investment income and volume, with adjusted earnings per share rising 21% to $2.34. MetLife also reported a 16% increase in net investment income and returned $875 million to shareholders through share repurchases and dividends. The company secured $12 billion in pension risk transfer mandates and expanded its operations in Asia and Latin America, reflecting strategic growth initiatives.
The most recent analyst rating on (MET) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.
On October 14, 2025, MetLife, Inc. filed a Certificate of Elimination with the Delaware Secretary of State to eliminate its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, which had been previously redeemed or reacquired. This action returned the shares to the status of authorized but unissued preferred stock, impacting the company’s capital structure by removing the specific designation of the Series G shares.
The most recent analyst rating on (MET) stock is a Buy with a $104.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.
MetLife, Inc. has disclosed preliminary information regarding its variable investment income for the quarter ended September 30, 2025, ahead of its official earnings release scheduled for November 5, 2025. The company estimates that it will meet its quarterly target of $425 million in variable investment income, which includes private equity, real estate, and other funds, as well as prepayment fees. However, these results are unaudited and subject to change, and stakeholders are advised to exercise caution as the actual results could differ materially from these preliminary figures.
The most recent analyst rating on (MET) stock is a Hold with a $84.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.
On September 15, 2025, MetLife, Inc. announced that it received an unsolicited mini-tender offer from Potemkin Limited to purchase up to 10,000 shares of its common stock at a price significantly below the market value. MetLife does not endorse this offer and advises shareholders against tendering their shares, as the offer price is 34.42% lower than the market price on September 12, 2025. The company highlights that mini-tender offers like Potemkin’s avoid many disclosure requirements and do not provide the same investor protections as larger offers. Shareholders who have already tendered their shares can withdraw them before the offer expires on October 7, 2025.
The most recent analyst rating on (MET) stock is a Buy with a $89.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.
On September 2, 2025, MetLife announced its decision to redeem all outstanding shares of its 3.850% fixed rate reset non-cumulative preferred stock, Series G, with a liquidation preference of $1,000 per share. The redemption will occur on September 15, 2025, and will not include accrued dividends, which will be paid separately. This strategic move may impact MetLife’s financial operations and stakeholder interests by altering its capital structure.
The most recent analyst rating on (MET) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.